European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Achieved lipid levels and long-term myocardial perfusion assessed by serial CZT-SPECT in post-PCI anterior myocardial infarction.","authors":"Ya Chang, Liu Li, Jie Zhou, Mei Wei, Qinghou Zheng, Le Wang, Yinge Zhan","doi":"10.1007/s00259-026-07793-7","DOIUrl":"10.1007/s00259-026-07793-7","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the association between achieved lipid levels, as an indicator of lipid residual risk, and longitudinal changes in myocardial perfusion and function in patients with acute anterior myocardial infarction (AMI) after percutaneous coronary intervention (PCI), using serial rest-stress CZT-SPECT imaging.</p><p><strong>Methods: </strong>In this retrospective cohort study, 462 anterior AMI patients post-PCI were categorized by their mean follow-up lipid levels into three groups: double-target achievement (LDL-C ≤ 1.4 mmol/L and reduction ≥ 50%; non-HDL-C < 2.2 mmol/L), single-target achievement (met LDL-C target only), and non-achievement. Myocardial perfusion was assessed by regadenoson stress/rest CZT-SPECT (D-SPECT camera) at 7 days and 12 months. Parameters included myocardial perfusion score (MPS), ischemic segment count, left ventricular ejection fraction (LVEF), and left ventricular end-diastolic volume (LVEDV). Major adverse cardiovascular events (MACE) were recorded.</p><p><strong>Results: </strong>The double-target group had significantly higher PCSK9 inhibitor use (66.0%) than the single-target (48.1%) and non-achievement groups (23.0%, P < 0.001). At 12 months, this group exhibited a lower MACE incidence (8.1% vs. 13.3% and 22.4%, P = 0.001), driven by reduced angina. Multivariable Cox regression confirmed that double-target achievement was independently associated with lower MACE risk (HR 0.38, P = 0.014) after adjusting for PCSK9 inhibitor use. Longitudinally, the double-target group showed the greatest improvement in MPS (ΔMPS - 5.0 ± 2.1) and LVEF compared to other groups (P < 0.001).</p><p><strong>Conclusion: </strong>Achieving stringent dual lipid targets post-PCI is associated with improved long-term myocardial perfusion, attenuated adverse remodeling, and lower MACE incidence. While these benefits are linked to intensive lipid-lowering therapy including PCSK9 inhibitors, achieving lipid targets remains an independent predictor of improved outcomes.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4059-4068"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring synaptic density patterns in cerebral small vessel disease: insights from [¹⁸F]SynVesT-1 PET imaging.","authors":"Ling Xiao, Tingting Zhao, Yi Yang, Jiayu Zhong, Di Liao, Boxin Zhang, Jiaxin Li, Ruxin Tu, Jiale Hou, Xingming Wang, Jie Feng, Ming Zhou, Shuo Hu, Jian Xia","doi":"10.1007/s00259-026-07808-3","DOIUrl":"10.1007/s00259-026-07808-3","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4015-4024"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study.","authors":"Zhaoguo Lin, Wenzhu Hu, Mengting Li, Zhidi Pan, Yuan Feng, Xiao Zhang, Biao Yang, Yongkang Gai, Dawei Jiang, Jianwei Zhu, Xiong Cai, Xiaoli Lan","doi":"10.1007/s00259-025-07739-5","DOIUrl":"10.1007/s00259-025-07739-5","url":null,"abstract":"<p><strong>Purpose: </strong>Accurate diagnosis of hepatocellular carcinoma (HCC) remains a clinical challenge. Glypican-3 (GPC3) is highly expressed in HCC but not in normal liver tissue, making it a promising target for PET-based molecular imaging, which may complement existing approaches for HCC diagnosis. In this study, we developed a new GPC3-targeted immunoPET radiotracer for noninvasive visualization of GPC3 expression and conducted a first-in-human, proof-of-concept evaluation in patients with HCC to assess its clinical feasibility.</p><p><strong>Methods: </strong>An anti-GPC3 antigen-binding fragment (Fab) was generated under Good Manufacturing Practice conditions and labeled with Gallium-68 (⁶⁸Ga) to obtain [⁶⁸Ga]Ga-aGPC3-Fab. In vitro assays, small-animal PET/CT scans, and ex vivo biodistribution experiments were conducted to examine its GPC3 targeting ability. Five patients with radiologically suspected or diagnosed HCC were enrolled in a pilot clinical study and underwent [⁶⁸Ga]Ga-aGPC3-Fab PET imaging. Radiotracer uptake in tumor and non-tumor tissues was quantitatively analyzed.</p><p><strong>Results: </strong>[⁶⁸Ga]Ga-aGPC3-Fab was synthesized with high radiochemical purity and demonstrated strong affinity and efficient internalization in GPC3-positive cells. It enabled clear tumor visualization in both subcutaneous and orthotopic GPC3-positive HCC mouse models. All five patients tolerated the PET procedure well, with no adverse effects. [⁶⁸Ga]Ga-aGPC3-Fab successfully detected intrahepatic metastases approximately 1 cm in diameter with high imaging contrast, including lesions that missed on magnetic resonance imaging.</p><p><strong>Conclusion: </strong>[⁶⁸Ga]Ga-aGPC3-Fab demonstrated a favorable safety profile and enabled effective visualization of GPC3-positive lesions. It may serve as a complementary approach to conventional imaging to improve the diagnostic accuracy of HCC.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov, NCT06383520. Registered on April 25, 2024 ( https://clinicaltrials.gov/study/NCT06383520 ).</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3891-3903"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis.","authors":"Emilia Zampella, Leandra Piscopo, Roberta Green, Valeria Cantoni, Carmela Nappi, Valeria Gaudieri, Elisa Caiazzo, Mariano Scaglione, Alberto Cuocolo, Michele Klain","doi":"10.1007/s00259-025-07726-w","DOIUrl":"10.1007/s00259-025-07726-w","url":null,"abstract":"<p><strong>Purpose: </strong>We performed a systematic review and meta-analysis to investigate the efficacy of peptide receptor radionuclide therapy (PRRT) by using radiolabeled somatostatin analogues in high grade gastro-entero-pancreatic neoplasms (GEP-NEN).</p><p><strong>Methods: </strong>All clinical studies published up to March 2025, including patients with grade 3 (G3) GEP-NEN treated with [¹⁷⁷Lu] Lu-DOTA-TATE and/or [⁹⁰Y] Y-SSA, were identified based on systematic searches in the PubMed and Embase databases. Eligible studies had to report at least one of the following outcomes: 1) response to therapy evaluated according to RECIST (version 1.1 as complete response, partial response, stable disease, progressive disease; 2) median progression free survival (PFS) with 95% confidence intervals (CI); 3) median overall survival (OS) with 95% CI. Objective response rate (ORR) and disease control rate (DCR) were considered as primary outcomes.</p><p><strong>Results: </strong>The final analysis included 7 studies accounting for a total of 317 patients with G3 disease (ranging from 18 to 112). Six studies evaluated response to therapy according to RECIST in 288 patients, and in 4 of them patients were also stratified according to ki67 values. The pooled ORR and DCR were 34% (95% CI: 22-46) and 64% (95% CI: 52-76), respectively. The funnel plot indicated no publication bias among these studies. Five studies reported in 239 patients median PFS with 95% CI, with a pooled estimate of 13.88 (95% CI: 10.33-18.64) months. Three studies fully reported in 174 patients median OS with 95% CI, with a pooled estimate of 29.95 (95% CI: 19.80-45.30) months.</p><p><strong>Conclusions: </strong>In patients with G3 GEP-NEN, PRRT may provide substantial disease control and response rates, and it seems able to delay the progression of the disease.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3799-3808"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145891996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of [¹⁸F]AlF-NOTA-FAPI PET/CT in guiding radiotherapy planning for stage I-IIIC lung cancer: A comparison with contrast-enhanced CT and [¹⁸F]FDG PET/CT.","authors":"Jingjie Qin, Chengqiang Li, Yong Huang, Yuqin Jin, Xiaoshan Liu, Xudong Hu, Jian Zhu, Junya San, Hongbo Wu, Xue Meng, Jinming Yu, Yuchun Wei","doi":"10.1007/s00259-025-07753-7","DOIUrl":"10.1007/s00259-025-07753-7","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the usefulness of [¹⁸F]AlF-labeled fibroblast activation protein inhibitor (FAPI), chelated with NOTA (denoted as [¹⁸F]AlF-NOTA-FAPI), positron emission tomography/computed tomography (PET/CT) for radiotherapy planning in lung cancer, we compared it with contrast-enhanced CT (CE-CT) and [¹⁸F]FDG PET/CT.</p><p><strong>Materials and methods: </strong>In this secondary analysis of a prospective trial, patients with stage I-III lung cancer who underwent [¹⁸F]AlF-NOTA-FAPI and CE-CT or [¹⁸F]FDG PET/CT scans within 2 weeks were selected. Gross tumor volume (GTV), clinical tumor volume (CTV), and planning tumor volume (PTV) were drawn for the primary tumor (GTVp) and involved lymph nodes (GTVnd) based on CE-CT, [¹⁸F]AlF-NOTA-FAPI PET/CT and [¹⁸F]FDG PET/CT. Organs at risk were evaluated and compared in intensity-modulated radiation therapy (IMRT) and intensity-modulated proton therapy (IMPT) plans.</p><p><strong>Results: </strong>Fifty-one patients (median age, 64 years; 38 males [74.5%]) were evaluated. Statistically significant differences in GTVs based on CE-CT, [¹⁸F]AlF-NOTA-FAPI PET/CT, and [¹⁸F]FDG PET/CT were found between each pair (all P < 0.05), except that no difference in GTVp was found between [¹⁸F]AlF-NOTA-FAPI and [¹⁸F]FDG PET/CT (P = 0.558). CE-CT-based GTVp values were significantly larger than those based on [¹⁸F]FDG PET/CT and [¹⁸F]AlF-NOTA-FAPI PET/CT due to the presence of obstructive pneumonia (n = 18; all P < 0.05). PTVall-IMRT based on CE-CT (351.98 ± 26.87) was significantly larger than that based on [¹⁸F]AlF-NOTA-FAPI PET/CT (329.98 ± 26.21; P = 0.03). PTVall-IMPT based on CE-CT (212.74 ± 18.73) was significantly larger than those based on [¹⁸F]FDG PET/CT (204.26 ± 19.34) and [¹⁸F]AlF-NOTA-FAPI PET/CT (196.99 ± 18.38), with P-values of 0.046 and 0.011, respectively. For IMRT, [¹⁸F]AlF-NOTA-FAPI PET/CT-based plans significantly reduced the radiation doses received by the heart, contralateral lung, and both lungs (all P < 0.05).</p><p><strong>Conclusion: </strong>[¹⁸F]AlF-NOTA-FAPI PET/CT shows promise as a valuable tool for radiotherapy planning in lung cancer, providing accurate target delineation and improved sparing of critical organs.</p><p><strong>Trial registration: </strong>This study was approved by the Clinical Research Ethics Committee of our institution.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3760-3774"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The malignancy risk of thyroid incidentalomas detected by [¹⁸F]FDG PET/CT lower than expected: a nationwide observational study in the Netherlands.","authors":"Hannelore I Coerts, Folkert J van Kemenade, Tessa M van Ginhoven, Menno R Vriens, M Medici, D Vriens, Bart de Keizer, Frederik A Verburg","doi":"10.1007/s00259-025-07714-0","DOIUrl":"10.1007/s00259-025-07714-0","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3653-3663"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145916836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An intra-patient contemporaneous comparison of ¹⁸F-piflufolastat and ¹⁸F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomy.","authors":"Luke T Nordquist, Jack R Andrews, Phillip H Kuo, Benjamin A Gartrell, David Josephson, Andrei S Purysko, Daniel R Saltzstein, Ram A Pathak, Neal Shore, James Sykes, Ross Penny, Phillip Davis, Brian T Helfand","doi":"10.1007/s00259-025-07732-y","DOIUrl":"10.1007/s00259-025-07732-y","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3529-3541"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147270134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential [¹⁸F]FAPI-42 and [¹⁸F]FDG uptake patterns distinguish desmoid tumours from GISTs on PET/CT imaging.","authors":"Chunhui Wu, Xiaoyan Wang, Xiaojie Lin, Andor W J M Glaudemans, Bart Cornelissen, Walter Noordzij, Xin Hu, Yu Zeng, Xiangsong Zhang, Xinhua Zhang","doi":"10.1007/s00259-025-07707-z","DOIUrl":"10.1007/s00259-025-07707-z","url":null,"abstract":"<p><strong>Background: </strong>Intra-abdominal desmoid tumours (IADT) can closely mimic gastrointestinal stromal tumours (GISTs), particularly in recurrence and metastases. However, differentiating these two diseases using radiological methods remains challenging. This study aimed to investigate the value of [¹⁸F]FAPI-42 PET/CT in differentiating IADT and GISTs compared to [¹⁸F]FDG PET/CT.</p><p><strong>Methods: </strong>This study retrospectively included a total of 24 patients (12 patients with IADT and 12 patients with recurrent/metastatic GISTs) who underwent two separate PET/CT scans using [¹⁸F]FAPI-42 and [¹⁸F]FDG, respectively. The differences in tumour SUV_max on [¹⁸F]FAPI-42 PET/CT (SUV_max-FAPI) and [¹⁸F]FDG PET/CT (SUV_max-FDG) and the ratio of tumour SUV_max on FAPI PET/CT to SUV_max on FDG PET/CT [SUV_max ratio (FAPI/FDG)] were compared between IADT and GISTs. Receiver operating characteristic (ROC) curve analyses were performed to evaluate the diagnostic performance of these parameters in differentiating IADTs from GISTs. Immunohistochemistry was used to verify FAP expression in all IADT lesions and GISTs lesions.</p><p><strong>Results: </strong>The SUV_max of IADTs on [¹⁸F]FAPI-42 PET/CT was significantly higher than that of GISTs [8.8 (7.2, 10.6) vs. 3.9 (2.8, 7.6), P = 0.045], whereas the SUV_max of IADTs on [¹⁸F]FDG PET/CT was significantly lower than that of GISTs [2.5 (1.9, 3.5) vs. 6.1 (3.6, 8.3), P = 0.007]. The SUV_max ratio (FAPI/FDG) of IADTs was significantly higher than that of GISTs [3.3 (2.2, 4.1) vs. 0.8 (0.3, 1.4), P < 0.001]. SUV_max-FAPI, SUV_max-FDG, and the SUV_max ratio (FAPI/FDG) achieved AUCs of 0.743, 0.819, and 0.896, with corresponding accuracies of 75.0%, 83.3%, and 87.5%, respectively, for distinguishing IADT from GISTs. Immunohistochemistry revealed significantly higher FAP expression in IADTs compared to GISTs (P = 0.002), with most IADTs showing strong (3+) staining (8/12, 66.7%), while GISTs primarily demonstrated weak (1+) or no staining (7/12, 58.3%).</p><p><strong>Conclusion: </strong>The distinct uptake characteristics of [¹⁸F]FAPI-42 and [¹⁸F]FDG observed in IADTs and GISTs provide preliminary evidence that these two tracers may offer complementary diagnostic information when evaluating desmoid tumours that mimic recurrent or metastatic GISTs.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3789-3798"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoperfusion in early-phase amyloid PET as a predictor of cognitive decline in Alzheimer's disease.","authors":"A Škorvagová, F Ribaldi, J Cerman, C Wang, M Scheffler, A J Mendes, C Wyss-Dominguez, V Garibotto, G Frisoni, R Andel, C Boccalini, J Hort","doi":"10.1007/s00259-025-07694-1","DOIUrl":"10.1007/s00259-025-07694-1","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4037-4049"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracking macrophages by direct and indirect ⁸⁹Zr PET imaging.","authors":"Vittorio De Santis, Renee Flaherty, Arshiya Banu, Paul Gape, Sophie Langdon, Alex Rigby, Aishwarya Mishra, George Firth, Truc T Pham, Amaia Carrascal-Miniño, Jana Kim, Kavitha Sunassee, Matthew Cleveland, Rafael T M De Rosales, Timothy H Witney, Michelle T Ma, Samantha Y A Terry","doi":"10.1007/s00259-025-07752-8","DOIUrl":"10.1007/s00259-025-07752-8","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4130-4142"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}